← Back to Clinical Trials
Recruiting NCT06938971

NCT06938971 Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (REACH)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06938971
Status Recruiting
Phase
Sponsor Rigshospitalet, Denmark
Condition Metastatic Colorectal Cancer (mCRC)
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2025-05-16
Primary Completion 2027-05-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Exercise training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2025-05-16 with a primary completion date of 2027-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary objective of this trial is to compare the effects of 18 weeks structured exercise training versus on control on healt-related quality of life in patients with mCRC undergoing first-line chemotherapy.

Eligibility Criteria

Inclusion criteria: \- Adults (≥18 years of age) schduled to undergo first-line chemotherapy for the treatment of metastatic colorectal cancer. Exclusion criteria : * Pregnancy. * A life expectancy of \< 6 months. * Absolute contraindications to maximal exercise, as per the recommendations by the Danish Society of Cardiology. * ECOG (Eastern Cooperative Oncology Group) performance status \> 2. * Inability to understand the Danish or English language. * Engagement in structured moderate-to-high aerobic exercise training for \>30 min \>1 times/week for the past 3 months at the time of inclusion.

Contact & Investigator

Central Contact

Casper Simonsen, Phd

✉ casper.simonsen@regionh.dk

📞 +45 35 45 76 41

Frequently Asked Questions

Who can join the NCT06938971 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Colorectal Cancer (mCRC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06938971 currently recruiting?

Yes, NCT06938971 is actively recruiting participants. Contact the research team at casper.simonsen@regionh.dk for enrollment information.

Where is the NCT06938971 trial being conducted?

This trial is being conducted at Copenhagen, Denmark, Herlev, Denmark, Hillerød, Denmark, Roskilde, Denmark.

Who is sponsoring the NCT06938971 clinical trial?

NCT06938971 is sponsored by Rigshospitalet, Denmark. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology